Today's After-Hours Movers:Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) 56% LOWER; announced top-line results from the companys Phase 2b ENCORE-NF clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE